Benzinga · Aug 28, 2026
Quoin Pharmaceuticals Stock Surges Friday: What's Happening?
Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial results and a major institutional financing.
QN
NASDAQ · QNRX
Quoin Pharmaceuticals, Ltd.
Healthcare · Biotechnology
$4.56
Up+$0.17 (+3.62%)
Updated Oct 7, 2026, 12:15 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.54M
- P/E ratio
- -0.54
- Dividend yield
- 0.00%
- 52-week range
- $3.25 – $41.80
- Volume
- 26.51K
- Avg. volume
- 656.17K
Price performance · QNRX
QNRX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
QNRX closed at $4.56 after 20 trading sessions, down 36.29% for the selected period.
- Last close
- $4.56
- Period change
- -36.29%
- Period low
- $4.47
- Period high
- $7.15
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.53 | $4.74 | $4.3636 | $4.555 | 26.51K |
| Oct 2, 2026 | $4.81 | $4.81 | $4.47 | $4.47 | 20.3K |
| Oct 1, 2026 | $4.685 | $4.80 | $4.5001 | $4.72 | 17.46K |
| Sep 30, 2026 | $4.88 | $5.09 | $4.55 | $4.56 | 139.25K |
| Sep 29, 2026 | $5.30 | $5.52 | $4.80 | $4.88 | 64.36K |
| Sep 28, 2026 | $6.40 | $6.41 | $5.26 | $5.26 | 70.29K |
| Sep 25, 2026 | $6.40 | $6.69 | $6.2466 | $6.43 | 11.34K |
| Sep 24, 2026 | $6.83 | $7.0999 | $6.12 | $6.38 | 39.53K |
| Sep 23, 2026 | $7.07 | $7.15 | $6.51 | $6.75 | 39.42K |
| Sep 22, 2026 | $6.98 | $7.1606 | $6.91 | $7.01 | 29.29K |
| Sep 21, 2026 | $6.92 | $7.14 | $6.76 | $6.90 | 52.19K |
| Sep 18, 2026 | $6.85 | $7.15 | $6.70 | $7.06 | 15.63K |
| Sep 17, 2026 | $6.92 | $7.22 | $6.4401 | $7.01 | 28.12K |
| Sep 16, 2026 | $6.8259 | $6.99 | $6.75 | $6.90 | 52.13K |
| Sep 15, 2026 | $6.89 | $6.89 | $6.2727 | $6.80 | 39.19K |
| Sep 14, 2026 | $6.71 | $6.95 | $6.66 | $6.88 | 10.29K |
| Sep 11, 2026 | $6.87 | $6.87 | $6.66 | $6.79 | 65.67K |
| Sep 10, 2026 | $6.84 | $7.00 | $6.58 | $6.90 | 31.14K |
| Sep 9, 2026 | $7.09 | $7.10 | $6.8437 | $6.97 | 59.39K |
| Sep 8, 2026 | $7.33 | $7.65 | $7.05 | $7.15 | 196.52K |
Latest QNRX news
The latest Smart Investors Daily articles mentioning QNRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
QNRX research
Overview
Company profile and research snapshot.
Company profile
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Lake Street | Buy | — |
| May 4, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Mar 15, 2024 | Maxim Group | Buy | — |
| Sep 7, 2022 | Alliance Global Partners | Buy | — |
| May 6, 2022 | Ladenburg Thalmann | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Market-Moving News for August 28th
AFRM: 13% | Affirm Holdings shares are trading higher after the company reported strong Q4 financial results. GAP: 16% | Gap shares are trading higher after the company reported better-than-expected Q2 adjusted EPS
Benzinga · Mar 11, 2026
Quoin Pharmaceuticals Receives FDA's Fast Track Designation To QRX003 Lotion To Treat Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan
defenseworld.net · Dec 4, 2025
Head to Head Review: Nutriband (NASDAQ:NTRB) vs. Quoin Pharmaceuticals (NASDAQ:QNRX)
Quoin Pharmaceuticals (NASDAQ: QNRX - Get Free Report) and Nutriband (NASDAQ: NTRB - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends. Insider and Institutional Ownership 8.6% of Quoin Pharmaceuticals
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
